What is the market's earnings forecast for Molina Healthcare next quarter?

What is Molina Healthcare's latest dividend and current dividend yield?

What were the key takeaways from Molina Healthcare's earnings call?

What guidance did Molina Healthcare's management provide for the next earnings period?

Did Molina Healthcare beat or miss consensus estimates last quarter?

What is Molina Healthcare's gross profit margin?

What factors drove the changes in Molina Healthcare's revenue and profit?

What were the key takeaways from Molina Healthcare’s earnings call?

- **EPS Downgrade**: 2025 EPS revised to $14 (from $19), with Marketplace underperformance (50% of reduction) and Medicaid rate/trend imbalance as key drivers.
- **Marketplace Restructuring**: 2026 rate increases of 15-45%, reduced footprint by 20%, targeting breakeven on $1.5-$2B revenue.
- **Medicaid Margin Outlook**: 2026 baseline MCR of 91.3%, with potential upside from 100bps rate catch-up ($4.50 EPS) and $8.65 embedded earnings pipeline.
- **Balance Sheet Strength**: Parent company cash of $108M, RBC ratios at 340%, and debt-to-EBITDA of 2.5x support growth initiatives.
- **Growth Catalysts**: Georgia/Texas Medicaid wins, Medicare duals expansion, and $54B M&A pipeline targeting low-margin, book-value acquisitions.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Adjusted EPS of $1.84, consolidated MCR of 92.6%, and premium revenue of $10.8 billion. Medicaid MCR of 92%, Medicare MCR of 93.6%, and Marketplace MCR of 95.6% reflect elevated medical cost trends across segments.
- **2025 Guidance Update**: Full year EPS revised to $14 (down from $19), driven by Marketplace underperformance (50% of EPS reduction) and Medicaid rate/trend imbalance. Full year MCR expected at 91.3%.
- **2026 Outlook**: Baseline EPS similar to 2025 guidance ($14), with potential upside from Medicaid rate catch-up (100bps of MCR yields $4.50 EPS) and embedded earnings ($8.65 per share pipeline). Marketplace revenue expected to decline to $1.5-$2 billion but targeted for breakeven margins.
- **Growth Initiatives**: $46 billion 2026 revenue target includes Georgia/Texas Medicaid wins, Medicare duals growth, and M&A pipeline of $54 billion opportunities. Share repurchases ($500M in Q3) reflect confidence in long-term margin targets despite short-term challenges.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net income of $278M, adjusted G&A ratio of 6.3%, and operating cash flow outflow of $237M due to risk corridor settlements. Parent company cash balance of $108M, RBC ratios at 340%, and debt-to-EBITDA of 2.5x.
- **2025 Guidance**: Full year premium revenue of $42.5B, MCR of 91.3%, and EPS of $14. Medicaid pretax margin of 3.2%, Medicare breakeven, and Marketplace negative pretax margin.
- **Capital Allocation**: Prioritized organic growth (Medicaid expansion, Medicare duals) over M&A, with disciplined approach to Marketplace exposure. 2026 G&A ratio expected to rise to 6.8% due to normalized compensation costs.

**【Q&A Highlights】**
- **Marketplace Strategy**: 2026 rate increases of 15-45% (30% average), reduced footprint by 20%, and exit from 50% of top-tier price positions to stabilize risk pool. Target mid-single-digit pretax margins on reduced revenue.
- **Medicaid Rates**: States 300-400bps underfunded, early 2026 rate cycle suggests modest catch-up (50bps above trend). LTSS, pharmacy, and behavioral health trends visible in rating cells support rate adequacy.
- **Embedded Earnings**: $8.65 per share pipeline includes $1 of implementation cost reversal and $0.40 Virginia contract loss. Partial realization in 2026 will depend on trend/rate alignment.
- **Medicare Performance**: MAPD margin improvement offset by FIDE/HIDE conversions. Bright ConnectiCare (MAPD) expected to reach target margins in 2026.
- **M&A Pipeline**: Full $54B pipeline with focus on low-margin, book-value acquisitions in struggling local plans. No plans to exit profitable Medicaid contracts despite industry-wide margin challenges.


MOH

MOH fundamentals

You can ask Aime